Literature DB >> 12542730

Collaborative study to calibrate hepatitis C virus genotypes 2-6 against the HCV International Standard, 96/790 (genotype 1).

J Saldanha1, A Heath.   

Abstract

BACKGROUND AND OBJECTIVES: A major requirement of a hepatitis C virus (HCV) RNA nucleic acid amplification technology (NAT) assay validation is the ability of the assay to detect the six major genotypes of HCV with equivalent sensitivities. The aim of this study was to characterize and calibrate an HCV genotype panel for use in such studies.
MATERIALS AND METHODS: Panels consisting of the first International Standard (IS) for HCV RNA NAT assays (96/790; HCV genotype 1a) and isolates of genotypes 2-6 were sent to 17 laboratories worldwide which use a variety of NAT tests, both qualitative and quantitative. The HCV RNA content of each panel member was determined and the mean titre calculated in International Units/ml (IU/ml).
RESULTS: The calculated mean titres (calibrated against the HCV International Standard), in log10 IU/ml, of the genotype 2-6 samples were 3.99, 3.81, 4.14, 4.18 and 4.61, respectively.
CONCLUSIONS: An HCV genotype panel, calibrated in IU/ml, has been established and should be valuable for assay validation. All the genotypes were detected by all the assays used, but it was not possible to demonstrate that the genotypes were detected with equal efficiencies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542730     DOI: 10.1046/j.1423-0410.2003.00260.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

Review 1.  International standards and reference materials for quantitative molecular infectious disease testing.

Authors:  Roberta M Madej; Jack Davis; Marcia J Holden; Stan Kwang; Emmanuel Labourier; George J Schneider
Journal:  J Mol Diagn       Date:  2010-01-14       Impact factor: 5.568

2.  Simultaneous visual detection of multiple viral amplicons by dipstick assay.

Authors:  Magda Anastassova Dineva; Daniel Candotti; Fiona Fletcher-Brown; Jean-Pierre Allain; Helen Lee
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera.

Authors:  Christian G Schüttler; Christine Thomas; Thomas Discher; Georg Friese; Jürgen Lohmeyer; Ralph Schuster; Stephan Schaefer; Wolfram H Gerlich
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  RNase-resistant virus-like particles containing long chimeric RNA sequences produced by two-plasmid coexpression system.

Authors:  Yuxiang Wei; Changmei Yang; Baojun Wei; Jie Huang; Lunan Wang; Shuang Meng; Rui Zhang; Jinming Li
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

Review 5.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.